Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies

Cancer Discovery

Volumn 2, Issue 5, 2012, Pages 395-397

  De Palma, Michele ^a,b   Nucera, Silvia ^b,c  

^a EPFL   (Switzerland)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN A4 PHOSPHATE; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; OMBRABULIN; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ARTICLE; CANCER INFILTRATION; CANCER RECURRENCE; DRUG EFFECT; DRUG RESISTANCE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HEMATOPOIETIC CELL; HUMAN; MALE; MOBILIZATION; NONHUMAN; PERIPHERAL CIRCULATION; REVASCULARIZATION; SINGLE DRUG DOSE; STEM CELL; TUMOR NECROSIS; TUMOR RESISTANCE; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HUMANS; MALE; STEM CELLS;

EID: 84866332370     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0137     Document Type: Article

References (18)

1. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
2. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
3. Yoder MC, Ingram DA. Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 2009;16:269-73.
4. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45.
5. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
6. De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006;1766:159-66.
7. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009;1796:33-40.
8. Fang S, Salven P. Stem cells in tumor angiogenesis. J Mol Cell Cardiol 2011;50:290-5.
9. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7.
10. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
11. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
12. Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, et al. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov 2012;2:434-49.
13. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789-95.
14. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrowderived myelomonocytic cells. Cancer Cell 2008;13:193-205.
15. Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 2008;105:6620-5.
16. Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res 2010;70:7273-82.
17. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011;121:1969-73.
18. Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med 2011;32:123-45.